Skip to main content

Advertisement

SpringerLink
Log in

MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer

  • Research
  • Published:
Journal of Cancer Research and Clinical Oncology Aims and scope Submit manuscript

Abstract

Objective

We aim to use the microRNA (miRNA, micro-ribonucleic acid) data of lung cancer tissues to establish a miRNA biomarker database for lung cancer that can be used for marker screening and analysis of lung cancer prognosis.

Methods

We obtained lung cancer-related data from The Cancer Genome Atlas (TCGA) and analyzed the miRNA expression profiles of lung cancer tissues and normal tissues using bioinformatics techniques to develop a new composite miRNA-based model for the prognostic assessment of lung cancer. The predictive power of this model was verified and evaluated based on grouping of data. We also performed RT-qPCR using lung cancer tissues from patients diagnosed with lung cancer.

Results

There was a significant difference between the miRNA expression profiles of lung cancer tissues and normal tissues adjacent to the cancerous lesions. The prognostic survival of patients with lung cancer was closely related to onset age and staging (p = 0.012) but was not related to gender (p = 0.39) and race (p = 0.51). Using three methods of survival model construction, we identified three miRNA composites, namely hsa-mir-21, hsa-mir-141, and has-mir-490, as markers for the prognosis of lung cancer. As confirmed by RT-qPCR, the expressions of hsa-miR-21-5p and hsa-miR-141-5p were upregulated, whereas hsa-miR-490-3p expression was downregulated in lung cancer lesion tissues.

Conclusion

The three miRNA composites identified, namely hsa-mir-21, hsa-mir-141, and hsa-mir-490, have the potential to serve as novel prognostic biomarkers and therapeutic targets for lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Availability of data and materials

The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request. We declared that materials described in the manuscript, including all relevant raw data, will be freely available to any scientist wishing to use them for non-commercial purposes, without breaching participant confidentiality.

References

  • Goldstraw P, Ball D, Jett JR et al (2011) Non-small-cell lung cancer. Lancet 378(9804):1727–1740

    Article  PubMed  Google Scholar 

  • Hu H, Zhou YF, Zhang M et al (2019) Prognostic value of RASSF1A methylation status in non-small cell lung cancer (NSCLC) patients: a meta-analysis of prospective studies. Biomarkers 24(3):207–216

    Article  CAS  PubMed  Google Scholar 

  • Lewis BP, Burge CB, Bartel DP (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120(1):15–20

    Article  CAS  PubMed  Google Scholar 

  • Li YQ, Chen YT, Li JJ et al (2017) Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Sci 108(7):1493–1503

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Li YQ, Guo TT, Zeng Y et al (2019) miR-490-3p inhibits the proliferation and invasion of Non-small-cell lung cancer cells by targeting TGFBR1. Lett Biotechnol 30(03):315–320

    Google Scholar 

  • Liang B, Zhao JY, Wang X (2017) A three-microRNA signature as a diagnostic and prognostic marker in clear cell renal cancer: an in silico analysis. PLoS ONE 12(6):e0180660

    Article  PubMed  PubMed Central  Google Scholar 

  • Liu Y (2014) The mechanism of miRNA-141 regulates Tiam1 gene in hepatocellular carcinoma metastasis. Southern Medical University

  • Paskeh MDA, Mirzaei S, Orouei S et al (2021) Revealing the role of miRNA-489 as a new onco-suppressor factor in different cancers based on pre-clinical and clinical evidence. Int J Biol Macromol 191:727–737

    Article  CAS  PubMed  Google Scholar 

  • Shi XH, Li X, Zhang H et al (2018) A Five-microRNA signature for survival prognosis in pancreatic adenocarcinoma based on TCGA data. Sci Rep 8(1):7638

    Article  PubMed  PubMed Central  Google Scholar 

  • Siegel RL, Miller KD, Fuchs HE et al (2021) Cancer Statistics, 2021. CA Cancer J Clin 71(1):7–33

    Article  PubMed  Google Scholar 

  • Tang X, Hu Y, Xu YH et al (2018) miR-498, miR-21 and miR-137 as potential serum markers in diagnosis of lung adenocarcinoma. China J Modern Med 28(04):39–44

    Google Scholar 

  • Wang J (2013) The study of expression and function of miR-141 in bladder urothelial carcinoma. Central South University

  • Wang DH, Fan ZS, Liu FL et al (2015) Hsa-miR-21 and Hsa-miR-29 in tissue as potential diagnostic and prognostic biomarkers for gastric cancer. Cell Physiol Biochem 37(4):1454–1462

    Article  CAS  PubMed  Google Scholar 

  • Wang LL (2019) LncRNA DLEU1 contributes to ovarian carcinoma tumorigenesis and development by interacting with miR-490–3p and altering CDK1 expression. China Medical University

  • Winther M, Alsner J, Tramm T et al (2015) Evaluation of miR-21 and miR-375 as prognostic biomarkers in esophageal cancer. Acta Oncol 54(9):1582–1591

    Article  CAS  PubMed  Google Scholar 

  • Xiao T, Jie ZG (2018) Research progress of microRNA-21 in gastric cancer. Chongqing Med 47(20):2733–2736

    Google Scholar 

  • Xu LJ (2014) hsa-miR-141 downregulates TM4SF1 to inhibit pancreatic cancer cell invasion and migration. Nanjing Medical University

  • Xu XH, Chen YC, Xu YL et al (2021) Garcinone E blocks autophagy through lysosomal functional destruction in ovarian cancer cells. World J Tradit Chin Med 7:209–216

    Google Scholar 

  • Yan H, Xin SB, Ma J et al (2019) A three microRNA-based prognostic signature for small cell lung cancer overall survival. J Cell Biochem 120(5):8723–8730

    Article  CAS  PubMed  Google Scholar 

  • Yang X, Su WM, Chen XY et al (2019) Validation of a serum 4-microRNA signature for the detection of lung cancer. Transl Lung Cancer Res 8(5):636–648

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang XB, Peng F (2017) Expression of microRNA-21 in peripheral blood and cancer tissues of patients with non-small cell lung cancer and its role in cancer inhibition by regulating PTEN protein. Chin J Gerontol 37(22):5571–5573

    CAS  Google Scholar 

  • Zhang C, Zhang CD, Ma MH et al (2018) Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol 24(11):1206–1215

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zhang YJ, Roth JA, Yu H et al (2019) A 5-microRNA signature identified from serum microRNA profiling predicts survival in patients with advanced stage non-small cell lung cancer. Carcinogenesis 40(5):643–650

    Article  CAS  PubMed  Google Scholar 

  • Zhao L, Zheng XY (2016) MicroRNA-490 inhibits tumorigenesis and progression in breast cancer. Onco Targets Ther 9:4505–4516

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Zheng KH, Zhou XY, Yu JL et al (2016) Epigenetic silencing of miR-490-3p promotes development of an aggressive colorectal cancer phenotype through activation of the Wnt/β-catenin signaling pathway [published correction appears in Cancer Lett. 2021 Oct 28;519:346-348]. Cancer Lett 376(1):178–187

    Article  CAS  PubMed  Google Scholar 

  • Zou YW, Jing CB, Liu L et al (2019) Serum microRNA-135a as a diagnostic biomarker in non-small cell lung cancer. Medicine (baltimore) 98(50):e17814

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to acknowledge the hard and dedicated work of all the staff that implemented the intervention and evaluation components of the study.

Funding

This work was supported by Natural Science Foundation of Shanghai (No.19ZR1476100), National Infrastructures for Translational Medicine (No.TMSK-2020-109), and Interdisciplinary Program of Medical Engineering Cross Fund (Nos. YG2019GD02, YG2019QNB23, and YG2019QNA52), Outstanding Youths Project of Shanxi Science and Technology Department (201901D211524).

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Fifth Clinical Medical College of ShanXi Medical University, No. 29 Shuangta East Street, Yingze District, Taiyuan, 030000, Shanxi, China

    Ruijie Wu & Gong Zhang

  2. School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, 200240, China

    Bohan Zhang, Mengju He & Yani Kang

Authors
  1. Ruijie Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bohan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mengju He
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yani Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conception and design of the research: GZ and YK. Acquisition of data: RW and BZ. Analysis and interpretation of the data: BZ and MH. Statistical analysis: BZ and MH. Obtaining financing: YK. Writing of the manuscript: RW and MH. Critical revision of the manuscript for intellectual content: GZ. All authors read and approved the final draft.

Corresponding author

Correspondence to Gong Zhang.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wu, R., Zhang, B., He, M. et al. MicroRNA biomarkers and their use in evaluating the prognosis of lung cancer. J Cancer Res Clin Oncol 149, 16753–16761 (2023). https://doi.org/10.1007/s00432-023-05404-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00432-023-05404-8

Keywords

Search

Navigation